Afamelanotide vs GHK-Cu
Both Afamelanotide and GHK-Cu are used for skin. Here's how their evidence, dosing, and regulatory status actually compare.
Afamelanotide
Evidence AAfamelanotide (Scenesse)
An FDA-approved selective MC1R agonist used to increase eumelanin density in erythropoietic protoporphyria patients. Off-label cosmetic tanning use is widespread internationally.
View full Afamelanotide profile →GHK-Cu
Evidence B+Copper Peptide GHK-Cu
A naturally occurring copper-binding tripeptide that modulates 4,000+ human genes. The most studied peptide for skin rejuvenation with both preclinical and clinical topical evidence.
View full GHK-Cu profile →Side-by-Side
| Attribute | Afamelanotide | GHK-Cu |
|---|---|---|
| Evidence Grade | A | B+ |
| FDA Status | FDA-approved (2019) for erythropoietic protoporphyria (EPP) | Not FDA-approved — available as cosmetic ingredient and research compound |
| Typical Dose | 16 mg subcutaneous implant every 2 months (clinical use) | 1–2 mg daily SC or topical (5 days on / 2 off) |
| Clinics Indexed | 14 | 145 |
| Categories | skin | anti-aging, skin, hair |
Key reported benefits — Afamelanotide
- ✓MC1R-selective tanning
- ✓FDA-approved for EPP
Key reported benefits — GHK-Cu
- ✓Collagen synthesis
- ✓Wrinkle reduction
- ✓Hair growth
- ✓Wound healing
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.